Scott Greenfeder

Scott Greenfeder is an accomplished executive in the field of regulatory affairs, currently serving as Vice President at Bayer since July 2018, where responsibilities include leading global regulatory and in-vitro diagnostic strategy for the oncology portfolio. Prior positions include Vice President and Head of Oncology Regulatory Affairs at Daiichi Sankyo, Executive Director of Regulatory Affairs Strategy at Daiichi Sankyo, and Director of Regulatory Affairs at Regeneron Pharmaceuticals. Scott has extensive experience at Merck, serving as Director and Liaison in Global Regulatory Affairs for both the Respiratory franchise and other roles. Notably, Scott directed a multidisciplinary team as a Research Fellow at Schering-Plough and Hoffmann-La Roche, focusing on cardiovascular and metabolic diseases. Academic qualifications include a Ph.D. in Molecular Biology from UMDNJ-New Jersey Medical School and a Bachelor's degree in Microbiology from Rutgers University.